I-Zoledronic Acid CAS 118072-93-8 Purity ≥99.7% API Factory High Quality
Nikeza Ngokuhlanzeka Okuphezulu kanye Nekhwalithi Ezinzile
Igama Lekhemikhali: I-Zoledronic Acid
I-CAS: 118072-93-8
I-Farnesyl Diphosphate enamandla (FPP) I-Synthase Inhibitor
Ikhwalithi ephezulu ye-API, Ukukhiqiza Kwezentengiso
| Igama Lekhemikhali | I-Zoledronic Acid |
| Omqondofana | ZOL 446, ZA, Zoledronate, CGP-4244, GP42446A, Zometa, Zomera;[1-Hydroxy-2-(1H-imidazol-1-yl)-ethylidene]bisphosphonic acid |
| Inombolo ye-CAS | 118072-93-8 |
| Inombolo yeCAT | I-RF-API90 |
| Isimo Sesitoko | Esitokweni, Isikali Sokukhiqiza Sifika Emakhulwini Amakhilogremu |
| I-Molecular Formula | I-C5H10N2O7P2 |
| Isisindo samangqamuzana | 272.09 |
| I-Melting Point | 193.0~204.0℃ |
| Ibhrendi | I-Ruifu Chemical |
| Into | Imininingwane |
| Ukubukeka | I-Crystalline Powder emhlophe ukuya kokumhlophe |
| Ukuhlonza | I-IR Spectrum yesampula ihambisana naleyo yezinga lesithenjwa |
| pH | 2.0~4.0 |
| Ukuncibilika | Incibilika Kancane ku-0.1N Sodium Hydroxide Solution, Incibilika Kancane Emanzini kanye no-0.1N Hydrochloric Acid, Ayincibiliki ku-Ethanol |
| Izinto Ezihlobene | |
| Noma yikuphi Ukungcola Komuntu Ngamunye | ≤0.10% |
| Ukungcola Okuphelele | ≤0.30% |
| Ukulahlekelwa Ekumisweni | 5.0%~7.0% |
| I-Chloride | ≤0.02% |
| I-Phosphite | ≤0.50% |
| I-Phosphate | ≤0.50% |
| Izinsimbi Ezisindayo | ≤10ppm |
| Ubumsulwa | ≥99.7% |
| Izinga Lokuhlola | I-Enterprise Standard |
| Ukusetshenziswa | I-API, FPP Synthase Inhibitor, Hypercalcemia of Malignancy (HCM) |
Iphakheji: Ibhodlela, isikhwama se-Aluminium foil, isigubhu seCardboard, 25kg/Drum, noma ngokwezidingo zekhasimende.
Isimo Sesitoreji:Gcina ezitsheni ezivaliwe endaweni epholile neyomile;Vikela ekukhanyeni, umswakama kanye nezinambuzane.
I-Zoledronic Acid (CAS 118072-93-8) iyi-bisphophonate enamandla farnesyl diphosphate (FPP) synthase inhibitor (IC50=20 nM).Ivimbela i-osteoclast-mediated bone resorption.Iphinde ivimbele ukusayinda kwe-Ras nokukhula kwesimila, futhi yenze i-apoptosis kumaseli omdlavuza we-pancreatic.Ihlehlisa inguquko ye-epithelial-mesenchymal futhi ivimbele ukuvuselelwa kweseli lomdlavuza webele ngokungasebenzi kwe-NF-κB.I-Zoledronic acid yavunywa yi-US FDA ngo-2001 ukuze kwelashwe i-hypercalcemia ye-malignancy, inkinga ye-metabolic engaba yingozi empilweni.I-Hypercalcemia ye-malignancy ingenzeka ezigulini ezingafika ku-50% ezitholakala zinomdlavuza webele osezingeni eliphezulu, i-myeloma eminingi, kanye nomdlavuza wamaphaphu weseli ongatheni.Lesi simo sivela lapho izingxenye zamakhemikhali ezikhiqizwa isimila zibangela ukugqugquzelwa kwama-osteoclasts.Lapho kunokwanda kokuwohloka kwamathambo, kuba khona ukukhululwa okuhambisanayo kwe-calcium ku-plasma.Lapho ukugxila kwe-calcium ku-serum yegazi kukhuphuka ngokushesha, izinso azikwazi ukusingatha ukugcwala, futhi imiphumela ye-hypercalcemia.I-Zoledronic acid yehlisa ngempumelelo ukugxila kwe-calcium ku-plasma ngokuvimbela ukubuyiswa kwethambo (ukuvimbela umsebenzi we-osteoclastic kanye nokungeniswa kwe-osteoclast apoptosis).Ukwengeza i-zoledronic acid igunyazwe yi-FDA yase-US ekwelapheni i-myeloma eminingi kanye nama-metastases amathambo ahambisana nomdlavuza oqinile osuselwe kwisimila (isb, i-prostrate namaphaphu).
